| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 12/18/2003 | US20030232970 Monoclonal antibody for treatment of tumor disorders; antitumor agents |
| 12/18/2003 | US20030232968 Incubating polyglutamic acid with polyetheyleneimine initiator; for drug screening/delivery |
| 12/18/2003 | US20030232893 Method of treating rosacea |
| 12/18/2003 | US20030232887 Preparation and use of a stable formulation of allosteric effector compounds |
| 12/18/2003 | US20030232884 New pharmaceutical formulation |
| 12/18/2003 | US20030232855 Such as N-(benzo(1,3)dioxol-5-ylmethyl)-7-methoxy-2-oxo-8-pentyloxy-1,2 -dihydroquinoline-3-carboxamide for stimulation of peripheral cell type cannabinoid receptors |
| 12/18/2003 | US20030232851 Viral treatment |
| 12/18/2003 | US20030232827 Therapeutic compounds |
| 12/18/2003 | US20030232797 Useful as immunomodulating and antiinflammatory compounds and in treatment of cardiovascular disease and cancer |
| 12/18/2003 | US20030232796 Nanoparticulate polycosanol formulations & novel polycosanol combinations |
| 12/18/2003 | US20030232784 Pyridine manganese amine complex macrocycle; treatment of rheumatoid arthritis |
| 12/18/2003 | US20030232780 Composition comprising an immunomodulatory molecule, which molecule comprises an antigen conjugated to an polynucleotide that contains at least one immunostimulatory nucleotide sequence; for modulating an immune response in vertebrates |
| 12/18/2003 | US20030232760 Conjugates useful in the treatment of prostate cancer |
| 12/18/2003 | US20030232753 Combined tissue factor methods for coagulation and tumor treatment |
| 12/18/2003 | US20030232750 Indolicidin peptide analogues containing at least two basic amino acids; bactericide |
| 12/18/2003 | US20030232748 Insulin aspart and insulin detemir in a specific ratio; antidiabetic agent |
| 12/18/2003 | US20030232742 A peptide containing residue of cytotoxic or cytostatic compound |
| 12/18/2003 | US20030232340 Nanoporous particle with a retained target |
| 12/18/2003 | US20030232095 Use enhancing bioavailability of oil-soluble, oil non-soluble or water-soluble nutraceuticals, foods, supplements, plant extracts, drugs, peptides, proteins or carbohydrates |
| 12/18/2003 | US20030232092 Liquid antacid compositions |
| 12/18/2003 | US20030232090 Anhydrous antifungal gel comprising polyhydric alcohol(s), a gelling agent and an antifungal azole such as econazole; treating oral and vaginal fungal and bacterial infections |
| 12/18/2003 | US20030232089 Gum increases the retention time of the active agent in the eye; e.g. konjac, scleroglucan, hydroxypropyl guar, propylene glycol alginate, sodium alginate, a trademarked carbomer, pectin, agarose and hydroxypropylmethyl cellulose |
| 12/18/2003 | US20030232088 Copolymer or interpolymer complex of a polycarboxylic acid bioadhesive polymer and a biodegradable polymer; for example a graft copolymer of (meth)acrylic acid and lactic acid; drug delivery applicatons; tampons |
| 12/18/2003 | US20030232085 Polymeric delivery agents and delivery agent compounds |
| 12/18/2003 | US20030232084 Administering parenterally effective dose of iron oxide complex with polyol or polyether formulated in biocompatible liquid so that upon administration provides minimal detectable free iron in and minimal incidence of anaphylaxis |
| 12/18/2003 | US20030232083 Modified release dosage form |
| 12/18/2003 | US20030232082 Modified release dosage forms |
| 12/18/2003 | US20030232080 For enhancing dissolution and absorption of active ingredients |
| 12/18/2003 | US20030232078 Formulation & dosage form for the controlled delivery of therapeutic agents |
| 12/18/2003 | US20030232077 Rapidly disintegrating tablet |
| 12/18/2003 | US20030232076 For encapsulating medication or other consumables; texture and chewability, storage qualities |
| 12/18/2003 | US20030232075 For therapy of clotting disorder |
| 12/18/2003 | US20030232074 For stimulating immune activation; for screening immunostimulatory compounds |
| 12/18/2003 | US20030232073 Enhanced drug delivery in transdermal systems |
| 12/18/2003 | US20030232072 Pharmaceutical composition and method for treating hypogonadism |
| 12/18/2003 | US20030232063 Aminosulfonic acid compounds for promoting desquamation of the skin |
| 12/18/2003 | US20030232048 Methods for treating chronic obstructive pulmonary disease (COPD) |
| 12/18/2003 | US20030232018 Stabilized formulations of adenovirus |
| 12/18/2003 | US20030232011 For use in therapy of cancer or an infectious disease |
| 12/18/2003 | US20030232010 Improved cytotoxic therapy |
| 12/18/2003 | CA2489153A1 Modified byrodin 1 with reduced immunogenicity |
| 12/18/2003 | CA2489076A1 Cryopreservation of haptenized tumor cells |
| 12/18/2003 | CA2488861A1 Use of orally-available prostacyclin derivatives for the production of a medicament for the treatment of disease states associated with bone marrow oedema |
| 12/18/2003 | CA2488753A1 Neutrophil imaging methods in cyctic fibrosis |
| 12/18/2003 | CA2488716A1 Intracellular delivery of biological effectors |
| 12/18/2003 | CA2488691A1 Extended release formulation of divalproex sodium |
| 12/18/2003 | CA2488618A1 Novel derivatives of androstane and androstene with ascorbic acid and use thereof in treating or preventing various conditions, diseases, and disorders |
| 12/18/2003 | CA2488617A1 Nanoparticulate sterol formulations and sterol combinations |
| 12/18/2003 | CA2488613A1 Novel formate salt of o-desmethyl-venlafaxine |
| 12/18/2003 | CA2488498A1 Nanoparticulate polycosanol formulations and novel polycosanol combinations |
| 12/18/2003 | CA2488403A1 Pharmaceutical formulation |
| 12/18/2003 | CA2488385A1 Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s) |
| 12/18/2003 | CA2488108A1 Liquid formulation of decitabine and use of the same |
| 12/18/2003 | CA2488059A1 Non-polymeric hematopoietic cell clots for delivery of active agents |
| 12/18/2003 | CA2487961A1 Method and composition for improving sensory characteristics of semisolid predominantly anhydrous |
| 12/18/2003 | CA2487889A1 Stabilised pharmaceutical compositions on the basis of polyoxyethylated castor oil and method for manufacturing the same |
| 12/18/2003 | CA2487413A1 Methods of treating angiogenesis, tumor growth, and metastasis |
| 12/18/2003 | CA2484514A1 Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions |
| 12/17/2003 | EP1371692A1 Auto inversible inverse Microlatex, process for its preparation and its utilization |
| 12/17/2003 | EP1371369A1 Compositions comprising remifentanil |
| 12/17/2003 | EP1371365A1 Emulsion/aggregation processes as methods for forming polymeric microspheres characterized by narrow particle size distribution for biomedical human and veterinary administration |
| 12/17/2003 | EP1371364A1 Proces for the preparation of a controlled release system |
| 12/17/2003 | EP1371363A1 Use of an enzymatically converted starch derivative as an encapsulating agent |
| 12/17/2003 | EP1371361A1 Novel suppository form comprising an acid-labile active compound |
| 12/17/2003 | EP1371357A2 Cosmetic and dermatological sunscreening compositions containing UV-absorbers and phyllosilicates |
| 12/17/2003 | EP1371289A1 Choline-silicic acid complex |
| 12/17/2003 | EP1370654A2 Chimpanzee erythropoietin (chepo) immunoadhesins |
| 12/17/2003 | EP1370588A2 Human monoclonal antibodies to fc alpha receptor (cd89) |
| 12/17/2003 | EP1370582A1 Peptide analogues of myelin basic protein epitopes in the treatment of experimental autoimmune encephalomyelitis (eae) and multiple sclerosis (ms) |
| 12/17/2003 | EP1370544A1 Nitric oxide donors based on metallic centres |
| 12/17/2003 | EP1370352A1 Method for encapsulating fine solid particles in the form of microcapsules |
| 12/17/2003 | EP1370302A1 Dry powder compositions comprising labelled particles for inhalation |
| 12/17/2003 | EP1370298A1 Elongated and multiple spacers in activatible prodrugs |
| 12/17/2003 | EP1370297A2 Method and composition |
| 12/17/2003 | EP1370296A2 Catecholate beta-lactam conjugates, method for producing the same and the use thereof |
| 12/17/2003 | EP1370295A2 Neutral and anionic colloidal particles for gene delivery |
| 12/17/2003 | EP1370293A2 Novel medicament compositions based on anticholinergics and on nk1 receptor antagonists |
| 12/17/2003 | EP1370291A1 Device and method for the photodynamic diagnosis of tumor tissue |
| 12/17/2003 | EP1370290A2 Molecular antigen array |
| 12/17/2003 | EP1370280A2 Stabilized interleukin 2 |
| 12/17/2003 | EP1370257A1 Composition for the prevention of osteoporosis comprising a combination of isoflavones and polyunsaturated fatty acids |
| 12/17/2003 | EP1370251A1 Topical patch preparation containing a delayed-type hypersensitivity inducer and methods for using the same |
| 12/17/2003 | EP1370249A1 Novel dendriticpolymers and their biomedical uses |
| 12/17/2003 | EP1370248A1 Compositions and methods for preventing platenet aggegation |
| 12/17/2003 | EP1370247A2 Taste masked pharmaceutical compositions |
| 12/17/2003 | EP1370246A2 Modulation of release from dry powder formulations |
| 12/17/2003 | EP1370241A1 Multi-lamellar emulsion(mle) for stabilizing dermatologically useful ingredients and external base preparations for general skin diseases utilizing the same |
| 12/17/2003 | EP1370239A1 New composition |
| 12/17/2003 | EP1370238A1 Liquid formulations for electrohydrodynamic spraying containing polymer and suspended particles |
| 12/17/2003 | EP1370228A2 Systems for delivering a cosmetic and/or therapeutic active to oral surfaces |
| 12/17/2003 | EP1370212A1 System and method for intranasal administration of lorazepam |
| 12/17/2003 | EP1370206A1 Devices for local and systemic delivery of active substances and methods of manufacturing thereof |
| 12/17/2003 | EP1294363B1 Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
| 12/17/2003 | EP1272470B1 Amorphous torasemide modification |
| 12/17/2003 | EP1196148B1 Process for microencapsulation of water soluble substances |
| 12/17/2003 | EP1171471B1 Enhanced gel strength methylcellulose |
| 12/17/2003 | EP1112065B1 Pharmaceutical composition comprising entacapone or nitecapone as well as a cross-linked cellulose deivative |
| 12/17/2003 | EP1032370B1 Porous hydroxyapatite particles as carriers for drug substances |
| 12/17/2003 | EP1028715B1 Dosage composition for nasal delivery comprising vibrio cholera zonula occludens toxin as absorption enhancer |
| 12/17/2003 | EP1009420B1 Conjugates useful in the treatment of prostate cancer |